Cisplatin and Tegafur in Recurrent Head and Neck Cancer: A phase II study

Abstract

A phase II study of cisplatin and tegafur in recurrent epidermoid head and neck cancer is presented. All patients were treated with cisplatin 100 mg/m² every 4 weeks. Twenty-nine received tegafur 750 mg/m² days 2–28 orally and 18 patients, who were unable to take tegafur orally, were treated with tegafur 1 500 mg/m² intravenously days 2–5. The response rate in the oral group was 28.5% and the median survival 29 weeks. The response rate in the intravenous group was 6% and the median survival was 17 weeks. We conclude that cisplatin and oral tegafur is active against head and neck cancer.